LYVE1 and neoplasm: HA receptors (especially CD44, hyaluronan-mediated motility receptor RHAMM, lymphatic vessel endothelial hyaluronic acid receptor 1 LYVE1) are activated in cancer cells to promote cell infiltration and tumor malignancy (Lokeshwar et al., 2014; Lee et al., 2020).